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L’aspergillose invasive (AI) est une importante cause de mortalité qui touche principalement les 
patients avec de cancers hématologiques et les transplantés. Parmi les différentes espèces 
d’Aspergillus, A. fumigatus et A. flavus causent la majorité des cas. Les Aspergilli de la section Usti 
(groupe ustus) sont des rares causes d’AI récemment rapportés comme émergents notamment 
parmi les transplantés recevant des prophylaxies antifongiques, surtout du posaconazole. Ce dernier 
médicament est prescrit en Suisse à titre préventif pour empêcher le développement d’aspergillose 
chez les transplantés de moelle.  
 Le but de cette thèse était de décrire l’épidémiologie européenne des AI par Aspergillus gr. ustus, 
leurs caractéristiques cliniques, les traitements administrés et leur outcome. Au niveau 
microbiologique, l’objectif était de décrire les espèces responsables d’AI, leur profil de susceptibilité 
aux antifongiques et de tester le synergisme de combinaisons antifongiques.   
Nous avons identifié des cas où un Aspergillus groupe ustus a été retrouvé dans un prélèvement 
clinique en Suisse et dans d’autres pays européens (19 hôpitaux, 8 pays) pendant les dernières 10 
années (2007‐2018).  Parmi 90 cas identifiés, 27 remplissaient les critères d’une AI probable ou 
prouvée (critères EORTC/MSG). Des cas additionnels (n=45) ont été identifié après une recherche 
systématique de la littérature. L’analyse poolée de ces 72 cas d’AI a montré que, dans la majorité de 
cas, les patients atteints étaient des transplantés de moelle osseuse (47%) ou d’organe solide (33%) 
et seulement 8% étaient neutropéniques. Quasi la moitié (47%) recevait une prophylaxie 
antifongique, principalement du posaconazole. Le poumon était l’organe principal touché mais des 
disséminations secondaires notamment au niveau cutané et cérébral étaient présentes dans 1/3 de 
cas. En ce qui concerne la prise en charge thérapeutique, l’antifongique principal administré (premier 
antifongique administré pour minimum 10 jours) était pour la majorité de l’amphotéricine B (39%) et 
du voriconazole (36%). La mortalité globale à 24 semaines était 58%. La mortalité était 
significativement plus haute chez les transplantés de moelle, quand l’infection était prouvée, et chez 
les receveurs d’amphotéricine B. Néanmoins les patients traités par amphotéricine B étaient plus 
immunosupprimés (plus de transplantés de moelle) avec des infections plus sévères (plus de cas 
prouvés et disséminés dans ce groupe), ce qui pourrait expliquer l’excès de mortalité dans cette 
catégorie.  
 Parallèlement, pour les cas pour lesquels la souche était disponible, celle‐ci a été envoyée à l’Institut 
de Microbiologie du CHUV à Lausanne. L’identification des souches au niveau de l’espèce 
(séquençage des gènes de la β‐tubuline et la calmoduline) a montré que la principale espèce du 
groupe ustus causant des IA était de loin A. calidoustus suivie par des cas isolés de A. pseudodflectus 
et A. ustus sensu stricto. Quant à la susceptibilité aux antifongiques testés par méthode CLSI, 
l’amphotéricine B était le médicament antifongique le plus actif in vitro. Les azoles étaient moins 
actifs, avec cependant une meilleure activité de l’isavuconazole, suivi par le voriconazole et le 
posaconazole. Pour une partie de souches d’Aspergillus calidoustus un synergisme a été démontré 
entre le voriconazole et le terbinafine in vitro (checkerboard microdilution method) validé in vivo 
dans un modèle d’infection de larves de Galleria mellonella.  
En conclusion, les AI par Aspergillus groupe ustus surviennent dans un contexte post‐transplantation, 
en général hors agranulocytose et souvent sous prophylaxie de posaconazole. La dissémination 
extra‐pulmonaire est fréquente. Le principal pathogène du groupe est A. calidoustus. Parmi les 
options thérapeutiques, l’amphotéricine B montre la meilleure activité in vitro mais les résultats issus 
de cette thèse montrent que les azoles (notamment l’isavuconazole ou le voriconazole seul ou en 
combinaison avec la terbinafine) restent une alternative thérapeutique à considérer pour des cas 
sélectionnés (AI probables, non‐disséminées, chez des hôtes moins immunosupprimés).  
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Invasive Aspergillosis Due to Aspergillus Section Usti: 
A Multicenter Retrospective Study
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Background. Aspergillus spp. of section Usti (A. ustus) represent a rare cause of invasive aspergillosis (IA). This multicenter 
study describes the epidemiology and outcome of A. ustus infections.
Methods. Patients with A. ustus isolated from any clinical specimen were retrospectively identified in 22 hospitals from 8 coun-
tries. When available, isolates were sent for species identification (BenA/CaM sequencing) and antifungal susceptibility testing. 
Additional cases were identified by review of the literature. Cases were classified as proven/probable IA or no infection, according to 
standard international criteria.
Results. Clinical report forms were obtained for 90 patients, of whom 27 had proven/probable IA. An additional 45 cases were 
identified from literature review for a total of 72 cases of proven/probable IA. Hematopoietic cell and solid-organ transplant recipi-
ents accounted for 47% and 33% cases, respectively. Only 8% patients were neutropenic at time of diagnosis. Ongoing antimold 
prophylaxis was present in 47% of cases. Pulmonary IA represented 67% of cases. Primary or secondary extrapulmonary sites of 
infection were observed in 46% of cases, with skin being affected in 28% of cases. Multiple antifungal drugs were used (consecu-
tively or in combination) in 67% of cases. The 24-week mortality rate was 58%. A. calidoustus was the most frequent causal agent. 
Minimal inhibitory concentrations encompassing 90% isolates (MIC90) were 1, 8, >16, and 4 µg/mL for amphotericin B, voriconazole, 
posaconazole, and isavuconazole, respectively.
Conclusions. Aspergillus ustus IA mainly occurred in nonneutropenic transplant patients and was frequently associated with 
extrapulmonary sites of infection. Mortality rate was high and optimal antifungal therapy remains to be defined.
Keywords.  Aspergillus ustus; Aspergillus calidoustus; Aspergillus pseudodeflectus; Aspergillus puniceus; Aspergillus insuetus.
Invasive aspergillosis (IA) is an important cause of morbidity and 
mortality among severely immunocompromised hosts, such as 
patients with hematologic cancer or transplant recipients [1–3]. 
The genus Aspergillus includes more than 300 species, but only few 
of them are common pathogens for humans. Aspergillus fumigatus 
is the main causal agent of IA, followed by A. flavus, A. niger, and 
A. terreus [1–3]. Aspergillus spp. of section Usti (group ustus, fur-
ther referred to as A. ustus) consist of about 20 species and repre-
sent a rare cause of IA [4–6]. However, they have been increasingly 
reported as potential pathogens over the last decade, especially in 
the setting of antimold active azole prophylaxis [7–9].
Aspergillus ustus IA is associated with high mortality rates 
[10]. The optimal antifungal treatment of these infections is 
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not well defined. Because these fungi exhibit decreased in vitro 
susceptibility to voriconazole and other mold-active azoles, 
amphotericin B formulations are recommended [11].
In this study, we report the results of a multicenter epidemio-
logical study of IA caused by A. ustus. These cases were pooled 
with those previously reported in the literature.
METHODS
Study Design and Data Collection
This was a retrospective multicenter study. In order to re-
cruit participating centers, a call for collaboration was 
launched via different networks including the following: (1) 
the Fungal Infection Network of Switzerland (FUNGINOS), 
the French National Reference Center for Invasive Mycoses 
and Antifungals (“Centre National de Référence des Mycoses 
Invasives et Antifongiques”), and the European Conference of 
Medical Mycology. Collaborators were asked to screen their 
local microbiology database and to report all cases for which 
an Aspergillus group ustus was isolated by culture in any clinical 
specimen. A standardized clinical report form (CRF) including 
demographic data, underlying diseases, immunosuppressive 
conditions, history of previous antifungal prophylaxis, charac-
teristics of fungal infection, results of radiological and microbi-
ological exams, antifungal treatment, and outcome was fulfilled 
for each case by the local investigator. Cases were classified as 
proven or probable IA or “colonization“ (absence of clinical/ra-
diological signs of IA) according to the criteria of the European 
Organization of Research and Treatment of Cancer (EORTC) 
and Mycoses Study Group (MSG) [12].
Microbiological Analyses
When available, clinical isolates were sent to the reference labo-
ratory of the study (Lausanne University Hospital, Switzerland) 
as a spore suspension or subculture on solid agar medium. 
Identification of the fungus as an Aspergillus group ustus (sec-
tion Usti) according to the taxonomic classification of Samson 
et  al [13] was confirmed and determined at the species level 
by partial sequencing of the B-tubulin (BenA) and calmod-
ulin (CaM) genes, as previously described [14]. Identity was 
obtained using the Basic Local Alignment Search Tool (BLAST) 
of the National Center for Biotechnology Information and was 
validated if results obtained by both approaches (BenA and 
CaM) were concordant. Antifungal susceptibility testing for 
azole drugs (voriconazole, posaconazole, and isavuconazole) 
and amphotericin B was performed at the reference labora-
tory for all available isolates by broth microdilution method 
according to the protocol of the Clinical and Laboratory 
Standards Institute [15]. Only 1 culture isolate per patient 
was tested. Aspergillus fumigatus specimen 4147 (UK Neqas 
for Microbiology, London, UK) served as a quality-control 
strain. Strains were incubated at 37°C (Aspergillus calidoustus, 
Aspergillus pseudodeflectus) or 30°C for those that were not able 
to grow at 37°C (all other species). Reading was performed at 
48 hours and the minimal inhibitory concentration (MIC) was 
defined as the concentration at which no residual growth was 
observed. MIC50 and MIC90 were defined as the MIC values 
encompassing 50% and 90% of the isolates, respectively.
Literature Review
A systematic review of the literature was performed to identify 
all published case reports and case series describing IA cases at-
tributed to A. ustus until 31 December 2018. A search was per-
formed in PubMed database (www.ncbi.nlm.nih.gov/pubmed) 
using the terms “Aspergillus ustus” and all the individual names 
of the 21 species belonging to group ustus [13]. Cases were in-
cluded if meeting the following criteria: (1) articles written in 
English, (2) presence of sufficient clinical data to classify the 
case as proven or probable IA according to EORTC-MSG cri-
teria [12], and (3) presence of data on antifungal therapy and 
outcome. Cases considered as localized fungal infections in im-
munocompetent patients (ie, ocular or cutaneous infections) 
were excluded. The clinical and microbiological data of the 
cases from the literature review were collected using the stand-
ardized CRF of the study.
Epidemiological and Outcome Analysis
Characteristics of patients and proven/probable IA were de-
scribed for the present case series and for cases of the lit-
erature review in separate and pooled analyses. The main 
antifungal therapy was defined as the first antifungal drug 
that was administered for at least 10 consecutive days fol-
lowing IA diagnosis. The response to antifungal therapy was 
assessed according to the EORTC-MSG clinical and radio-
logical criteria, with success defined as complete or partial 
response and failure as stable disease, progression, or death 
[16]. All-cause mortality was recorded for up to 24 weeks 
after IA diagnosis. The timing for the endpoint of response 
to therapy and mortality/survival was considered as the 
latest assessment occurring within the period of 24 weeks 
following IA diagnosis. The contribution of IA to death was 
considered as probable in case of progressive or stable in-
fection (ie, failure) according to EORTC-MSG assessment of 
therapeutic response at time of death.
Statistical Analysis
Fisher’s exact test and nonparametric test (Mann-Whitney) 
were used for the comparison of categorical and continuous 
variables, respectively. A 2-sided P value ≤.05 was considered as 
statistically significant.
Ethical Statement
The study was approved by Swissethics (project 2017-01562). 
All the CRFs and clinical samples were assigned a study code 
by the local investigator and sent anonymously to the reference 
center of the study (Lausanne University Hospital).
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RESULTS
Characteristics of Patients and Invasive Aspergillosis
Ninety CRFs of patients for which an Aspergillus group ustus was 
isolated from a clinical specimen were obtained from 22 hospital 
centers in 8 countries from 2007 to 2018 (Supplementary Table 
1). Two cases were withdrawn from the analysis because of a 
lack of clinical data. Of the 88 remaining cases, 27 fulfilled the 
EORTC-MSG criteria of proven (n = 9) or probable (n = 18) IA.
Our search in the medical literature identified 45 cases of 
proven (n = 28) and probable (n = 17) IA due to A. ustus from 
29 publications, including 24 single case reports and 5 case se-
ries (from 2 to 6 cases) from 1974 to 2018 [5, 7–10, 17–40].
Characteristics of patients and infections of all proven/prob-
able IA cases (n = 72) are shown in Tables 1 and 2. Compared 
with the present case series (n = 27), cases reported from the 
literature (n = 45) included a higher proportion of proven IA 
(62% vs 33%, P = .02). Other comparisons between both groups 
did not show statistically significant differences. Overall, most 
patients were hematopoietic cell transplant (HCT) or solid-
organ transplant (SOT) recipients (47% and 33%, respectively) 
(Table 1). A majority of patients (84%) were receiving immu-
nosuppressive therapies, and only 8% of patients were neutro-
penic at time of IA diagnosis. Ongoing prophylaxis or treatment 
with antimold active azoles for at least 7 days before IA diag-
nosis was present in 47% of cases (consisting of posaconazole 
and voriconazole in 62% and 24% of them, respectively). 
Characteristics of IA episodes are described in Table 2. The lung 
was the primary site of infection in 76% of cases. Primary or 
Table 1. Epidemiological Characteristics of Patients with Aspergillus ustus Proven/Probable Invasive Aspergillosis
Current Study  
(n = 27)
Literature Review  
(n = 45)
Overall  
(n = 72)
Demographic characteristics  
 Age, years 55 (19–73) 48 (9–77) 48 (9–77)
 Female 8 (30) 15 (33) 23 (32)
Underlying host conditions
 Hematologic malignancy 17 (63) 24 (53) 41 (57)
  Acute leukemia 6 (35) 11 (46) 17 (41)
  Myelodysplastic syndrome 2 (12) 3 (12) 5 (13)
  Lymphoproliferative disorder 8 (47) 1 (4) 9 (22)
  Other/not specified 1 (6) 9 (38) 10 (24)
 Hematopoietic cell transplantation 14 (52) 20 (44) 34 (47)
  Allogeneic 11 (78) 19 (95) 30 (88)
   Graft-vs-host disease 10 (91) 15 (79) 25 (83)
  Autologous  3 (22) 1 (5) 4 (12)
 Solid-organ transplantation 7 (26) 17 (38) 24 (33)
  Lung 1 (15) 8 (47) 9 (37)
  Heart 4 (56) 4 (23) 8 (34)
  Kidney 2 (29) 2 (12) 4 (17)
  Liver 0 (0) 2 (12) 2 (8)
  Lung and heart 0 (0) 1 (6) 1 (4)
 Solid tumor 1 (3) 2 (4) 3 (4)
 Autoimmune disease 1 (3) 0 (0) 1 (1) 
Immunosuppressive conditions
 Neutropenia (PMNs <500/µL) 1 (4) 5 (11) 6 (8)
 Immunosuppressive therapy 19/23 (82)a 34/40 (85)a 53/63 (84)a
  Including corticosteroids 16 (84) 31 (91) 47 (89)
  Including calcineurin inhibitors 10 (53) 23 (68) 33 (62)
  Including mycophenolate mofetil 4 (21) 15 (44) 19 (36) 
Ongoing antifungal therapyb
 Antimold active azole 13 (48) 21 (47) 34 (47)
  Posaconazole 8 (61) 13 (62) 21 (62)
  Voriconazole 5 (39) 3 (14) 8 (24)
  Itraconazole 0 (0) 5 (24) 5 (14)
 Other 0 (0) 5 (11)c 5 (7)c
Numbers represent absolute numbers (%) for proportions or medians (range) for continuous variables. 
Abbreviation: PMN, polymorphonuclear neutrophil.
aData not available for all cases.
bFor ≥7 days before and ongoing at diagnosis.
cCaspofungin (2), amphotericin B (3).
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secondary extrapulmonary sites of infection were observed 
in 46% of cases. Lesions of skin/soft tissue and brain were 
present in 28% and 14% of cases, respectively. Disseminated 
infection (>1 organ affected) was observed in 33% of cases. 
In 18% of cases, IA was considered as mixed with another 
documented pathogenic mold (Table  2). Data on serum 
galactomannan were available for 33 patients, and the test 
was positive (optical density ≥0.5) in 28 (85%) of them. 
Results of galactomannan test in bronchoalveolar lavage fluid 
were available for 10 patients, of which 7 (70%) were positive 
(optical density ≥0.5).
Invasive Aspergillosis Management and Outcomes
Patients were treated with multiple antifungal drugs (either 
sequentially or consecutively) in 67% of cases (Table  2). Of 
64 evaluable cases, the main antifungal therapy (as defined 
above) was an amphotericin B formulation in 39% of cases and 
voriconazole in 36% of cases. Compared with patients receiving 
voriconazole as the main treatment (n = 23), those treated with 
amphotericin B (n  =  25) were predominantly HCT patients 
(64% vs 30% in the voriconazole group, P = .02), with a higher 
proportion of proven (72% vs 26%, P = .003) and disseminated 
(56% vs 13%, P = .002) IA.
Combination therapies were administered to 26 of 64 (41%) 
patients and consisted of an echinocandin in addition to 
voriconazole (n = 9) or amphotericin B (n = 9) or a combina-
tion of amphotericin B and voriconazole (n = 8).
The overall response rate to antifungal therapy was con-
sidered as a failure (ie, stable disease or progression) in 55% of 
cases. Forty-two (58%) of the 72 patients with proven/probable 
IA died within 24 weeks (Table  2). The contribution of IA to 
death was considered as probable in 81% of cases.
Overall mortality was higher among patients with HCT 
versus non-HCT (79% vs 47%, P  =  .01), in IA classified as 
proven versus probable (77% vs 47%, P = .01), and in those re-
ceiving amphotericin B as the main antifungal regimen versus 
another drug (80% vs 46%, P = .02).
Microbiological Data
Aspergillus ustus isolates were obtained for 22 of 27 (81%) 
proven/probable IA cases of the present case series. Multilocus 
sequencing (BenA and CaM) identified A.  calidoustus as 
the pathogenic species in 19 of 22 (86%) cases. Aspergillus 
pseudodeflectus (n = 2, probable pulmonary IA) and Aspergillus 
ustus sensu stricto (n = 1, proven soft-tissue IA) accounted for 
the remaining cases. For the IA cases of the literature review, 
identification was available only at the section level (Aspergillus 
group ustus) in 29 (64%) cases. Identification at the species 
level (using various sequencing approaches) was provided for 
16 (36%) cases: 13 A. calidoustus, 2 Aspergillus granulosus, and 
1 A. pseudodeflectus.
Table 2. Characteristics of Aspergillus ustus Proven/Probable Invasive 
Aspergillosis
Current Study 
(n = 27)
Literature  
Review  
(n = 45)
Overall  
(n = 72)
Type of infection
 EORTC-MSG classification    
  Proven/probable cases 9 (33)/18 (67) 28 (62)/17 (38) 37 (51)/35 (49)
 Extent of infection    
   Single site/disseminated  
 (>1 site)
21 (78)/6 (22) 27 (60)/18 (40) 48 (67)/24 (33)
 Sites of infectiona    
  Lung 24 (88) 31 (69) 55 (76)
  Skin/soft tissue 4 (15) 16 (35) 20 (28)
  Brain 3 (11) 7 (15) 10 (14)
  Bone 2 (7) 2 (4) 4 (5)
  Otherb 1 (4) 4 (8) 5 (7)
Aspergillus spp.
 A. calidoustus 19 (70) 13 (29) 32 (45)
 A. pseudodeflectus 2 (7) 1 (2) 3 (4)
 A. ustus 1 (4) 0 (0) 1 (1)
 A. granulosus 0 (0) 2 (4) 2 (2)
 Group ustusc 5 (19) 29 (65) 34 (48)
Concomitant infections 
 All coinfectionsa 14 (52) 18 (40) 32 (44)
   Fungald 8 (57) 5 (28) 13 (41)
   Bacterial 7 (50) 8 (44) 15 (47)
   Viral 3 (21) 8 (44) 11 (34)
Management of IA 
 Antifungal treatment 22 (81) 42 (93) 64 (89)
   Multiple antifungal 
   drugse
12 (55) 31 (74) 43 (67)
 Main antifungal therapyf    
  Voriconazole 8 (36) 15 (36) 23 (36)
    In combination with 
 echinocandin
0 (0) 9 (60) 9 (39)
  Amphotericin B 9 (41) 16 (38) 25 (39)
   Lipid formulation 9 (100) 10 (62) 19 (76)
   Deoxycholate 0 (0) 6 (38) 6 (24)
    In combination with 
 echinocandin
3 (33) 6 (38) 9 (36)
   Amphotericin B and 
 voriconazole
2 (9) 6 (14) 8 (12)
  Otherg 3 (14) 5 (12) 8 (12)
Surgery 4 (15) 7 (15) 11 (15)
Outcome 
 Treatment failure 14 (52) 26 (58) 40 (55)
 24-Week mortality 14 (52) 28 (62) 42 (58)
Probable contribution of IA 
to death
12 (86) 22 (78) 34 (81)
Numbers represent absolute numbers (%) for proportions or medians (range) for contin-
uous variables. 
Abbreviations: EORTC-MSG, European Organization for Research and Treatment of Cancer/
Mycoses Study Group; IA, invasive aspergillosis.
aMore than 1 possible.
bOther sites (>1 possible): liver, cardiac valve, myocardium, thyroid, eye.
cIsolates not available for sequencing (phenotypic identification at section/group level only).
dA. fumigatus, A. flavus, A. nidulans, A. versicolor, A. melleus, A. tamarii, A. novofumigatus, 
Mucorales, Geotrichum spp., Scopulariopsis spp., Homographiella verticillata.
eMultiple antifungal drugs used in combination or consecutively.
fFirst antifungal drug administered for ≥10 consecutive days following IA diagnosis.
gPosaconazole (n = 4), itraconazole (n = 2), micafungin (n = 2).
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Among the 61 cases of the present series that were classi-
fied as colonization, 35 isolates were available for sequencing. 
Aspergillus calidoustus was the predominant species (80%), 
while several other species (A.  pseudodeflectus, A.  ustus, 
Aspergillus insuetus, Aspergillus puniceus, Aspergillus keveii) 
were also isolated from respiratory samples.
Antifungal susceptibility testing was performed for 55 iso-
lates of the present case series (including 22 proven/probable 
IA cases and 33 cases of colonization). MIC50, MIC90, and 
MIC ranges for all species and antifungal drugs are shown 
in Table 3. Amphotericin B was the most active drug in vitro 
(MIC50/MIC90: 0.5/1  µg/mL). Among triazoles, isavuconazole 
showed somewhat better activity (2/4 µg/mL), compared with 
voriconazole (8/8  µg/mL) and posaconazole (16/>16  µg/mL). 
No notable differences were observed across species.
DISCUSSION
Invasive aspergillosis due to A.  ustus are rare infections. Our 
review of the literature identified 45 cases published as in-
dividual case reports or small cases series. The present study 
describes 27 additional cases of proven or probable IA, which 
represents the largest case series until now. These cases identi-
fied via a screening of microbiological databases may be more 
representative of the actual epidemiology of A. ustus infections 
compared with selected individual case reports. However, the 
proportion of proven IA was lower. In order to address this 
potential bias, characteristics of patients and infections have 
been provided separately for the 2 approaches in addition to 
the pooled analysis of all cases. It is also important to mention 
that our enrollment strategy could not be representative of the 
global epidemiology of A.  ustus IA, with a majority of cases 
from Europe (mainly France and Switzerland).
Overall, A.  ustus IA cases were mainly observed in 
nonneutropenic transplant (HCT or SOT) patients receiving 
long-term immunosuppressive therapy. Our analysis confirms 
the propensity of these molds to cause extrapulmonary IA af-
fecting mainly the skin/soft tissues and brain. About half of 
cases were breakthrough IA among patients receiving antimold 
active azoles. The emergence of A. ustus in the setting of azole 
prophylaxis has been suggested in a recent report [7]. Our study 
does not provide data about the actual incidence or proportion 
of A.  ustus IA but suggests that these infections remain rare 
events.
Despite the existence of about 20 species in section Usti, phy-
logenetic analyses have suggested that most cases of infection 
were actually due to A. calidoustus [4]. While A. calidoustus rep-
resented the main offending pathogen in our case series, some 
other species of section Usti were also documented as the cause 
of IA. Similar to A. calidoustus, A. pseudodeflectus is able to grow 
at 37°C and was the cause of 2 probable IA cases. This species 
was previously documented as a causal agent of IA in a single 
case report [17]. Aspergillus ustus sensu stricto, which is not 
thermotolerant at 37°C, was shown for the first time to be the 
cause of a proven infection limited to the skin and soft tissues. 
The different species of section Usti exhibited similar antifungal 
susceptibility profiles, with amphotericin B being the most ac-
tive drug in vitro, as previously reported [41]. In addition, our 
study provides data about the novel triazole isavuconazole, for 
which MICs were somewhat lower compared with those of 
voriconazole or posaconazole.
Our results show that the rates of therapeutic failure and 
overall mortality of A.  ustus IA are high. Interestingly, while 
these Aspergillus species exhibit some intrinsic level of resistance 
to azoles, voriconazole was considered as the main antifungal 
therapy in a substantial proportion of cases. Despite a relatively 
favorable outcome in this subgroup, these patients were mainly 
non-HCT patients with apparently less severe disease according 
to the classification of IA (probable only) and the extent of in-
fection (not disseminated), in comparison to patients treated 
with an amphotericin B formulation who exhibited a lower sur-
vival rate. Because of the small number of cases, the retrospec-
tive design, the large time window of inclusion (1973–2018), 
and the absence of case matching for underlying diseases and 
severity of infection, a comparative analysis of drug efficacy was 
Table 3. Results of Antifungal Susceptibility Testing for the Different Aspergillus ustus Species
MIC50/MIC90; 
Range, µg/mL
 Voriconazole Posaconazole Isavuconazole Amphotericin B
A. calidoustus (n = 44) 8/8;  
2–16
16/>16;  
4 to >16
2/4  
2/4; 0.5 to >16
0.5/1;  
0.25–2
A. pseudodeflectus (n = 5) 4–16 4 to >16 2–8 0.25–1
A. ustus (n = 2) 2 8 2–4 0.5
A. insuetus (n = 2) 4–8 8 to >16 4 0.25
A. keveii (n = 1) 4 8 8 0.25
A. puniceus (n = 1) 4 8 2 0.25
All group ustus (n = 55) 8/8;  
2–16
16/>16;  
4 to >16
2/4;  
0.5 to >16
0.5/1;  
0.25–2
For isolates with n ≤ 5, only ranges were provided.
Abbreviations: MIC50, minimal inhibitory concentration encompassing 50% of isolates; MIC90, minimal inhibitory concentration encompassing 90% of isolates. 
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not possible. Our previous analysis in an invertebrate model 
of A.  calidoustus infection showed that amphotericin B and 
voriconazole were equally effective in rescuing infected Galleria 
mellonella larvae [42]. Only the combination of voriconazole 
and terbinafine demonstrated some synergism in vitro and in 
vivo (Galleria model), but this combination is marginally used 
in clinical practice. Therefore, the optimal antifungal therapy 
for A. ustus IA remains uncertain in the absence of a prospec-
tive randomized matched-control trial, which seems very dif-
ficult to carry out. Experts usually recommend the use of an 
amphotericin B formulation [11]. Because these infections are 
often breakthrough IA under posaconazole and voriconazole 
prophylaxis, continuation with an azole drug should be avoided 
in these cases. However, voriconazole with or without the addi-
tion of terbinafine might still have a place for the management 
of selected cases with less severe immunosuppression and di-
sease or those who are intolerant to amphotericin B. The role 
of isavuconazole, exhibiting somewhat lower MICs compared 
with other azoles, remains also to be explored.
In conclusion, this analysis provides the largest dataset about 
the epidemiology of A. ustus IA with some clinically relevant 
information about the categories of patients at risk and the clin-
ical presentation of disease. While our results outline the par-
ticularly high rate of therapeutic failure and mortality of these 
infections, the optimal therapeutic approach remains to be 
defined.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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Efficacy of Antifungal Monotherapies and Combinations
against Aspergillus calidoustus
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ABSTRACT Invasive fungal infections due to Aspergillus calidoustus with decreased
azole susceptibility are emerging in the setting of azole prophylaxis and are associ-
ated with poor outcomes. We assessed the in vitro activity of antifungal drugs used
alone or in combinations against A. calidoustus and found a synergistic effect be-
tween voriconazole and terbinafine at concentrations within the therapeutic range.
An invertebrate Galleria mellonella model of A. calidoustus infection tended to sup-
port the potential benefit of this combination.
KEYWORDS Aspergillus ustus, Galleria mellonella, Usti, amphotericin B, invasive fungal
infections, synergism, terbinafine, voriconazole
Invasive aspergillosis is a severe infection affecting immunocompromised hosts. WhileAspergillus fumigatus remains the predominant pathogenic species, Aspergillus calid-
oustus (section Usti) is an emerging pathogen exhibiting some degree of intrinsic azole
resistance and causing breakthrough infections in patients receiving antimold prophy-
laxis (1–3). Dissemination to soft tissues or the brain is frequently observed in A.
calidoustus infections, which are often refractory to antifungal therapy and associated
with high mortality rates (3). As a result, many patients are treated with combinations
of antifungals expecting some synergistic interactions, which has not been demon-
strated. The aim of this study was to assess the in vitro and in vivo efficacy of antifungal
monotherapies and combinations against A. calidoustus.
(Preliminary results of this research were presented as a poster at the 28th European
Congress of Clinical Microbiology and Infectious Diseases [ECCMID], Madrid, Spain, 21
to 24 April 2018 [4]).
Ten clinical isolates of A. calidoustus were selected for this study. Species identifi-
cation was confirmed by partial sequencing of the beta-tubulin (BenA) and calmodulin
(CaM) genes, as previously described (5). Drugs were obtained as powders (Sigma-
Aldrich, St. Louis, MO), dissolved in dimethyl sulfoxide (DMSO) for a stock concentration
of 5 mg/ml, and stored at 20°C. In vitro antifungal susceptibility testing was per-
formed according to the M38-A3 Clinical and Laboratory Standards Institute (CLSI)
broth microdilution method (6). Plates were incubated at 35°C and read by visual
inspection at 48 h. Synergy testing was performed by the checkerboard dilution
method as previously described, with interactions defined as synergistic, indifferent, or
antagonistic for a fractional inhibitory concentration index (FICI) of 0.5, 0.5 to 4, and
4, respectively (7). Amphotericin B, voriconazole, posaconazole, isavuconazole, and
terbinafine were tested alone and in combinations. Experiments were performed in
duplicates. In the case of discordant results (FICI difference of 0.05), a third replicate
was performed, and the result was expressed as the FICI for which two concordant
results were obtained.
An invertebrate model of A. calidoustus infection was performed in Galleria mello-
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nella larvae (Bait Express GmbH, Basel, Switzerland) as previously described (8). Groups
of 20 larvae with a weight ranging from 350 to 400 mg were infected with a single dose
of 3  106 spores in 40 l phosphate-buffered saline (PBS). Antifungal drugs were
injected 2 h later as a single 40-l dose of amphotericin B (5 mg/kg), voriconazole (10
mg/kg), terbinafine (5 mg/kg), or a combination of voriconazole (10 mg/kg) and
terbinafine (5 mg/kg). Drug doses were selected based on previous pharmacokinetic
models in G. mellonella or extrapolated from human dosage (9, 10). Larvae were
incubated at 37°C, and survival was assessed twice daily during 7 days postinfection.
Performing a single injection of antifungal treatment 2-h postinfection, we analyzed the
survival curve by the Gehan-Breslow-Wilcoxon test with GraphPad Prism software,
giving more power to deaths at early time points.
MICs of amphotericin B, voriconazole, posaconazole, isavuconazole, and terbinafine
are shown in Table 1. The combination of voriconazole and terbinafine was tested on
all strains, with a synergistic effect (FICI, 0.5) in 9/10 strains (Table 1). Other drug
combinations were tested on strains 1 and 2, with the following FICI results:
posaconazole-terbinafine, 0.5 (synergistic); isavuconazole-terbinafine, 0.4 and 0.6 (syn-
ergistic and indifferent), amphotericin B-voriconazole, 3 (indifferent); and amphotericin
B-terbinafine, 4 (antagonistic). Caspofungin, exhibiting only very modest fungistatic
activity against A. calidoustus, showed indifferent interactions with either voriconazole
or amphotericin B (FICI, 2).
To further assess the efficacy of antifungal drugs against A. calidoustus, we tested
the different monotherapies and the voriconazole-terbinafine combination in a G.
mellonella infection model using A. calidoustus strain 1. The experiment was performed
in duplicates (Fig. 1A and B). Each individual drug (amphotericin B, voriconazole, and
terbinafine) demonstrated a significant effect compared with the untreated group, but
there was no superiority of one drug compared with another. The voriconazole-
terbinafine combination was associated with a markedly improved survival compared
with the untreated group in both experiments (P  0.0001). Compared with mono-
therapies, the superiority of the combination therapy reached statistically significant P
values against terbinafine alone in the first experiment and against both voriconazole
and amphotericin B in the second experiment.
This in vitro and in vivo analysis of the activity of antifungal drugs used alone or in
combination against Aspergillus calidoustus lead to some interesting conclusions. First,
despite better in vitro activity, amphotericin B did not demonstrate superiority over
voriconazole in an invertebrate model of infection. Indeed, voriconazole demonstrated
a significant in vivo efficacy against this fungus despite MIC values that are usually
considered at the limit or above the therapeutic range of concentrations. The addition
of terbinafine to voriconazole or other mold-active azoles (posaconazole and isavu-
conazole) resulted in a moderate positive interaction at the limit of the synergistic
criteria (FICI approximately 0.5). Low concentrations of terbinafine (0.12 to 0.25 g/ml)
were sufficient to lower the voriconazole MIC from 4 to 8 g/ml to 1 to 2 g/ml, which
TABLE 1 In vitro activity of antifungal drugs alone and combined against 10 Aspergillus calidoustus strains
Strain
MIC (g/ml) for antifungal drugsa:
MICs (g/ml) for VOR-TBFb FICI for VOR-TBFbAMB VOR POS ISA TBF
1 1 4 8 2 0.5 1, 0.12 0.5
2 1 4 8 2 1 1, 0.25 0.5
3 1 8 16 2 0.5 1, 0.25 0.6
4 0.5 4 16 4 1 1, 0.25 0.5
5 0.5 8 16 4 1 2, 0.25 0.5
6 0.25 8 16 4 0.5 2, 0.12 0.5
7 1 2 8 2 0.5 0.5, 0.12 0.5
8 1 2 8 2 1 0.25, 0.25 0.4
9 2 8 4 2 1 2, 0.25 0.5
10 0.5 8 16 4 0.5 2, 0.12 0.5
aAMB, amphotericin B; VOR, voriconazole; POS, posaconazole; ISA, isavuconazole; TBF, terbinafine.
bMIC of voriconazole and terbinafine when used in combination. FICI, fractional inhibitory concentration index.
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corresponds to targeted therapeutic serum concentrations for the treatment of invasive
aspergillosis (11, 12). The invertebrate model of A. calidoustus infection tended to
support the potential benefit of the voriconazole-terbinafine combination despite
some discrepant results between the two experiments. Such variability of the fitness of
the Galleria spp. larvae is frequently observed (8), which may be due to their hetero-
geneous genetic background, age and stage of seasonal cycle, or mode of preservation.
Despite variability, the voriconazole-terbinafine combination was associated with the
highest survival rate compared with the untreated group in both experiments (P 
0.0001) and was the only treatment arm showing some significant improvement
compared with the others. The second experiment, associated with a higher early
mortality rate, may be more representative to assess significant differences between
treatment arms. In this last experiment, the voriconazole-terbinafine combination was
significantly more effective compared with both voriconazole or amphotericin B alone.
Albeit not tested in the Galleria mellonella model, other drug combinations, such as
amphotericin B associated with voriconazole or terbinafine, resulted in indifferent or
even deleterious interactions in vitro.
Topical or systemic terbinafine has been anecdotally used as adjunctive antifungal
treatment for primary cutaneous infections due to A. calidoustus in the past (13, 14).
Terbinafine is known for its accumulation in soft tissues and can also penetrate the
hematoencephalic barrier (15); thus, it represents an interesting adjuvant therapy for A.
calidoustus infections that frequently affect the soft tissues and brain (29% and 12% of
cases, respectively) (3). The combination of voriconazole and terbinafine has already
FIG 1 Efficacy of antifungal drugs in a Galleria mellonella model of A. calidoustus infection. Survival curves of G. mellonella larvae injected
with 3  106 spores of A. calidoustus and a single dose of antifungal drug 2-h postinfection. Larvae were monitored for survival twice daily.
Groups of 20 larvae were used each time. (A and B) The results of two independent experiments. (C) Data were analyzed by
Gehan-Breslow-Wilcoxon test. *, P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001. PBS, phosphate-buffered saline (no drug); AMB,
amphotericin B; VOR, voriconazole; TBF, terbinafine.
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demonstrated some synergism against other Aspergillus spp. or other molds (e.g., Scedospo-
rium spp.) and has been used for the treatment of invasive scedosporiosis (16–18).
A. calidoustus infection remains a rare but often fatal disease, for which the optimal
antifungal treatment is still debated. Because of the intrinsic level of azole resistance of this
fungus, amphotericin B is usually the preferred first-line antifungal therapy, but its use is
limited by nephrotoxicity and the lack of an oral formulation for prolonged therapy.
Although this study was performed with a limited number of isolates, our results showed
that, despite better in vitro antifungal activity, amphotericin B did not demonstrate better
efficacy compared with voriconazole in a Galleria mellonella model of infection. Terbinafine
may be considered as an adjunctive therapy to voriconazole for its in vitro synergistic effect
and possibly improved in vivo efficacy; however, combination with amphotericin B should
be avoided because of in vitro antagonistic interactions.
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Abstract: The Aspergilli of section Usti (group ustus) are represented by over 20 species, of which
Aspergillus calidoustus is the most relevant human pathogen. Invasive aspergillosis (IA) caused by
these fungi is rare but could represent an emerging issue among the expanding population of patients
with long-term immunosuppression receiving antifungal prophylaxis. Clinicians should be aware
of this unusual type of IA, which often exhibits distinct clinical features, such as an insidious and
prolonged course and a high occurrence of extra-pulmonary manifestations, such as skin/soft tissue or
brain lesions. Moreover, these Aspergillus spp. pose a therapeutic challenge because of their decreased
susceptibility to azole drugs. In this review, we outline the microbiological and clinical characteristics
of IA due to Aspergillus spp. of section Usti and discuss the therapeutic options.
Keywords: Aspergillus ustus; Aspergillus pseudodeflectus; Aspergillus granulosus; Aspergillus insuetus;
Aspergillus puniceus; Aspergillus keveii; invasive aspergillosis
1. Introduction
Fungi of the genus Aspergillus represent the most important pathogenic molds for humans, causing
invasive aspergillosis (IA) in patients with impaired immune defenses. While over 300 Aspergillus spp.
have been described, the vast majority of IA cases are attributed to less than five species, consisting
mainly of A. fumigatus (60–80% cases) and A. flavus, A. niger (or related cryptic species) and A. terreus
for most of the remaining cases [1–4]. A recent study however suggested that epidemiology of IA may
evolve as a consequence of the widespread use of anti-mold azole prophylaxis (i.e., posaconazole or
voriconazole) with emergence of Aspergillus of section Usti (group ustus) exhibiting natural resistance
to these antifungals [5]. This section includes over 20 species that are ubiquitous molds found in the
indoor and outdoor environment [6]. Notably, they were the most frequent Aspergillus spp. found in
drinking water distribution systems in Norway, including from hospital tap water [7]. A. ustus and
related species were also frequently recovered from water-damaged buildings and from caves affected
by human activities [8,9]. While the first case of IA due to Aspergillus of section Usti was described in
1974 [10], these infections have been increasingly reported in the literature since 2000 [11,12].
The aim of this review is to provide a practical summary of what infectious diseases specialists
and microbiologists should know about Aspergillus spp. of section Usti for their daily practice.
J. Fungi 2020, 6, 84; doi:10.3390/jof6020084 www.mdpi.com/journal/jof
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2. Taxonomy and Microbiology
Based on phylogenetic analyses, there are currently 26 recognized Aspergillus species belonging to
section Usti (Table 1) [6,8,13]. Most of them, including A. ustus sensu stricto, are unable to grow at
37 ◦C and therefore are not considered as human pathogens. Actually, most cases of human infections
that were attributed to A. ustus in the literature, were secondarily reassigned to a novel distinct species,
A. calidoustus, which is able to grow at 37 ◦C [14]. Two other closely related species, A. pseudodeflectus
and A. granulosus, are also thermotolerant at human body temperature and were also found to be
able to cause invasive infections in humans [11,15–17]. A. ustus sensu stricto was also isolated from a
patient with aspergillosis localized to the skin and soft tissue [11]. Other non-thermotolerant species of
section Usti that were isolated as colonizers or contaminants from clinical specimens include A. insuetus,
A. puniceus and A. keveii [11].
Table 1. The 26 Aspergillus species of section Usti and their pathogenic role in humans.
Isolated in Clinical Specimens Environmental Samples Only
Proven/probable IA 1 cases
A. calidoustus 2
A. pseudodeflectus 3
A. granulosus 4
A. ustus 5
Colonization only
A. insuetus
A. keveii
A. puniceus
A. amylovorus
A. asper
A. baeticus
A. californicus
A. carlsbadensis
A. cavernicola
A. collinsii
A. deflectus
A. egyptiacus
A. elongatus
A. turkensis
A. germanicus
A. heterothallicus
A. kassunensis
A. lucknowensis
A. monodii
A. pseudoustus
A. subsessilis
A. thessauricus
IA: invasive aspergillosis. 1 Proven probable invasive aspergillosis according to the criteria of the European
Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group (MSG) [18]. 2 Major cause
of IA in humans [11]. 3 Three reported cases of probable IA [11,15]. 4 Two reported cases of proven IA [16,17].
5 Single reported case of proven soft tissue IA [11].
Morphological characteristics of Aspergillus spp. of section Usti are usually reliable for identification
at the section level. However, species identification would require partial sequencing of the beta-tubulin
(BenA) or calmodulin (CaM) genes, which is not routinely available in most diagnostic microbiology
laboratories [11]. Standard sequencing methods targeting the internal transcribed spacer (ITS) or
26-28S rDNA are not reliable enough for identification beyond the section level. Experience with
matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) is
limited for these rare species and misidentification has been reported [19].
Most species of section Usti will grow at 25–30 ◦C. Higher temperature (37 ◦C) allows distinguishing
A. calidoustus or other thermotolerant species (e.g., A. pseudodeflectus, A. granulosus) from nonpathogenic
species. Colonies are usually apparent between 2 and 5 days of growth. Macroscopic aspects on
standard fungal culture media (e.g., Czapek yeast extract agar, Sabouraud or potato dextrose agar)
show velvety greyish to brown cinnamon colonies (Figure 1, left) [6,20]. The yellowish reverse color
with presence of yellow-brown soluble pigment is typical but can be absent for some species and/or
according to the culture medium (Figure 1, middle). Under the microscope, conidial heads are usually
short and loosely columnar with biseriate phialides (Figure 1, right) [6,20]. Conidia typically harbor
rough ornamentation. Some specific characteristics (Hülle cells, Ehrlich reaction, growth on creatine,
production of extrolites) may help distinguishing the different species, but these methods require the
expertise of reference laboratories [6,20].
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Figure 1. Morphological aspects of Aspergillus calidoustus. Macroscopic aspect of the colony on 
Sabouraud dextrose agar medium, top (left) and reverse (middle). Microscopic aspect (1000 ×) of a 
conidial head (staining: lactophenol blue) (right). Note: rough ornamentation of conidia is not visible 
here and could better visualized by scanning electron microscopy. 
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exhibit in vitro activity at concentrations that are usually at the upper limit or beyond the 
therapeutic range of concentration. Notably, isavuconazole displays somewhat higher activity 
compared to voriconazole and posaconazole (this latter one being the less active): MIC50/MIC90 of 2/4 
µg/mL, 8/8 µg/mL and 16/>16 µg/mL, respectively [11]. The fungistatic activity of echinocandins is 
comparable to that against other Aspergillus spp. with micafungin and anidulafungin exhibiting 
lower MIC compared to caspofungin [21]. The novel long-lasting echinocandin rezafungin (CD101) 
and the glucan synthase inhibitor ibrexafungerp (SCY-078) are also active against Aspergillus of 
section Usti [22,23]. Terbinafine has good in vitro activity (MIC 0.25 to 1 µg/mL), and its combination 
with voriconazole was synergistic in vitro and in a Galleria mellonella model of infection [24]. 
3. Epidemiology and Clinical Characteristics 
IA caused by Aspergillus section Usti (further referred as A. ustus IA) remains a rare disease. In a 
cohort of 218 culture positive IA from the Transplant-Associated Infection Surveillance Network 
(TRANSNET), A. ustus complex species were the fifth cause of IA being responsible for 2.7% of all 
cases [25]. In the Prospective Alliance Therapy (PATH) registry, these species accounted for 0.8% of 
cases (rank 6th) [4]. In a single center study of 24 microbiologically documented breakthrough 
invasive mold infections, A. ustus accounted for 12.5% of all episodes and 43% of IA [5]. Outbreaks of 
A. ustus IA have been reported among hematopoietic stem cell transplant (HSCT) or solid-organ 
transplant (SOT) recipients [26,27]. While these data are mainly derived from North American 
cohorts, the incidence of A. ustus IA in other regions of the world is not well described. 
The largest epidemiological description of proven/probable A. ustus IA included 72 cases, of 
which 45 were obtained from previous published case reports or small case-series (1974–2018) and 
27 were collected via a screening of microbiological databases of 22 European hospital centers 
(2007–2018) [11]. Most patients were non-neutropenic transplant recipients (47% HSCT and 33% 
SOT recipients) receiving long-term immunosuppressive therapy (anti-calcineurin drugs and/or 
corticosteroids). About half of them (47%) had ongoing anti-mold azole prophylaxis (mainly 
posaconazole) at time of diagnosis. This observation is consistent with the above mentioned 
Figure 1. Morphological aspects of Aspergillus calidoustus. Macroscopic aspect of the colony on
Sabouraud dextrose agar medium, top (left) and reverse (middle). Microscopic aspect (1000 ×) of a
conidial head (staining: lactophenol blue) (right). Note: rough ornamentation of conidia is not visible
here and could better visualized by scanning electron microscopy.
Antifungal susceptibility testing shows very similar profiles across species [11,21]. Amphotericin B
is the most active drug in vitro with minimal inhibitory concentration encompassing 50% (MIC50)
and 90% (MIC90) isolates of 0.5 and 1 µg/mL, respectively [11]. Azoles exhibit in vitro activity at
concentrations that are usually at the upper limit or beyond the therapeutic range of concentration.
Notably, isavuconazole displays somewhat higher activity compared to voriconazole and posaconazole
(this latter one being the less active): MIC50/MIC90 of 2/4 µg/mL, 8/8 µg/mL and 16/>16 µg/mL,
respectively [11]. The fungistatic activity of echinocandins is comparable to that against other
Aspergillus spp. with micafungin and anidulafungin exhibiting lower MIC compared to caspofungin [21].
The novel long-lasting echinocandin rezafungin (CD101) and the glucan synthase inhibitor
ibrexafungerp (SCY-078) are also active against Aspergillus of section Usti [22,23]. Terbinafine has good
in vitro activity (MIC 0.25 to 1 µg/mL), and its combination with voriconazole was synergistic in vitro
and in a Galleria mellonella model of infection [24].
3. Epidemiology and Clinical Characteristics
IA caused by Aspergillus section Usti (further referred as A. ustus IA) remains a rare disease.
In a cohort of 218 culture positive IA from the Transplant-A sociated Infection Surveillance Network
(TRANSNET), A. stus complex species were the fifth cau e of IA being responsible for 2.7% of all
cases [25]. In the Prospective Allian e Therapy (PATH) registry, thes species accounted for 0.8% of
(rank 6th) [4]. In a single center study of 24 microbiologically documented breakthrough invasive
mold infections, A. ustus account d for 12.5% of all episodes and 43% of IA [5]. Outbr aks of A. ustus IA
have been reported among hematopoietic stem cell transplant (HSCT) or solid- rgan transplant (SOT)
recipients [26,27]. While these dat are mainly derived from North Americ cohorts, the inci ence of
A. ustus IA in other regio s of the world is not w ll described.
The largest epid miological description of pr ven/probable A. ustus IA included 72 cases, of which
45 were obtained from previous published case rep rts or sm ll case-series (1974–2018) and 27 were
collected via a screening of microbiological databases of 22 European hospital cent rs (2007–20 ) [11].
Most patients were non-neutropenic transplant recipients (47% HSCT and 33% SOT recipients)
receiving long-term immunosuppressive therapy (anti-calcineurin drugs and/or corticosteroids).
About half of them (47%) had ongoing anti-m ld azole prophylaxis (mainly posaconazole) at time f
diagn sis. This observation is consistent with the above me tioned epidemiological studies suggesting
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a higher prevalence of A. ustus IA among transplant patients and those receiving anti-mold azole
prophylaxis [5,26,27].
A. ustus IA were disseminated (i.e., more than one organ affected) in 33% cases. While the lung
was affected in 76% cases, primary or secondary extra-pulmonary sites of infections were frequently
observed. Skin and/or soft-tissue lesions were present in 28% cases and cerebral aspergillosis in 14%
cases [11]. Serum galactomannan was positive in 85% patients. Overall mortality was high (58% at
6 months, with IA being considered as a major or partial cause of death in 81% of cases) [11].
In summary, A. ustus IA exhibit some distinct clinical features compared to other IA, as they seem
to affect mainly non-neutropenic transplant patients receiving anti-mold active prophylaxis and have
a propensity to cause primary or secondary skin lesions or other extra-pulmonary foci of infection.
The clinical case presented in Box 1 is illustrative of these characteristics and shows the insidious
course of this fungal disease with notably the positive galactomannan in serum preceding the clinical
signs of infection by several weeks or months.
Box 1. Illustrative case of Aspergillus calidoustus invasive aspergillosis.
A 64-year old woman underwent allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Three years later, she was treated by two chemotherapy cycles (FLAG and FLAG-IDA) for two consecutive
relapses of the hematologic cancer, followed by maintenance therapy with azacitidine and sorafenib. She was
receiving tacrolimus and corticosteroids for cutaneous and digestive graft versus host disease (GVHD).
Antifungal prophylaxis with posaconazole was administered with appropriate trough concentrations (>0.5 mg/L).
During follow-up, an increase in serum galactomannan was observed with a first positive value at 1.8 (optical
density index), while she was asymptomatic. Three months later, she noticed painless skin nodules on her
right leg, upper back and axillary hollow. Serum galactomannan at this time was persistently positive (6.43).
Histopathological examination of the nodules revealed subcutaneous granulomas with mycelial elements.
Cultures of skin biopsy grew a mold identified as an Aspergillus group ustus by sequencing of the 26-28S rDNA
and identified at species level as Aspergillus calidoustus by partial sequencing of the beta-tubulin (BenA) and
calmodulin (CaM) genes. Total body CT and 18F-FDG PET/CT did not reveal any other lesion.
The patient received multiple antifungal treatment lines (liposomal amphotericin B with caspofungin,
voriconazole with terbinafine, liposomal amphotericin B with caspofungin and terbinafine). Following surgical
excision of all skin nodules, she experienced a recurrence of infection with suspected fungal arthritis of the right
shoulder, which was treated by intra-articular injections of amphotericin B. A reduction of the immunosuppressive
regimen was attempted, but the patient experienced a flare of GVHD and ultimately died. While all clinical foci
of infection had resolved, serum galactomannan was persistently positive at time of death. Autopsy however
did not reveal evidences of remaining invasive mold infection.
4. Treatment
As previously mentioned, the species of Aspergillus section Usti exhibit high MICs to the azole
drugs, which represent the first-line antifungal therapy of IA [28]. As a result, current guidelines
recommend the use of amphotericin B lipid formulations, which are the most active drug in vitro [28].
In practice, antifungal management is difficult with frequent use of multiple antifungal agents,
either consecutively or in combination (Box 1) [11]. Interestingly, our analysis of the 72 A. ustus IA
cases show that voriconazole was used as first-line therapy (i.e., first antifungal drug administered
for at least 10 consecutive days) in a substantial proportion of cases [11]. These patients actually
seemed to be less immunocompromised (non-HSCT recipients) and less severely ill with IA that
were non-disseminated and classified as probable only, in comparison to those who were treated by
amphotericin B. Not surprisingly, the mortality rate was significantly lower in this subgroup compared
to amphotericin B-treated patients. Because of these evident biases in retrospective non-matched
cohorts, it is not possible to draw conclusions about comparative drug efficacy. Nonetheless, it is
noteworthy that voriconazole and amphotericin B were equally effective in a Galleria mellonella model
of A. calidoustus infection [24]. The novel triazole isavuconazole seems to be somewhat more active
than voriconazole in vitro, but clinical experience with this drug for the treatment of A. ustus IA is still
very limited [29].
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The potential benefit of drug combination is also debated. Indeed, an echinocandin, in combination
with amphotericin B or voriconazole, was part of the first-line antifungal regimen in about one third of
cases [11]. Some patients also received a combination of amphotericin B and voriconazole. Overall,
mortality was high among patients receiving combination therapies, which may actually reflect the
severity of the initial presentation of the disease in these cases. In vitro, these drug combinations were
classified as indifferent [24]. Only the combination of voriconazole and terbinafine demonstrated a
synergistic interaction in vitro and in the Galleria model [24]. While clinical experience with terbinafine
for invasive mold infections is very limited, this drug may have an interest as adjunctive treatment
for A. ustus IA because of its high penetration in skin and soft tissue and possibly in the brain [30].
Similarly, the combination of voriconazole and terbinafine has been used for other refractory mold
diseases, such as scedosporiosis, although its benefit was not demonstrated [31].
From these observations, we can conclude that the optimal therapeutic approach of A. ustus IA
would still deserve further investigations. Notably, this is another example that in vitro data do not
necessarily correlate with clinical efficacy, as it has been previously shown for other difficult-to-treat
mold infections [32]. Non-pharmacological parameters, such as recovery of the immune system or
the initial severity of the disease with delay in diagnosis may represent the predominant predictors
for outcome.
Our personal approach of A.ustus IA, as described in Table 2, is to consider liposomal amphotericin
B as the first-line treatment, especially for severe cases. However, we consider that voriconazole or
isavuconazole (this latter drug being even more active in vitro) alone or combined with terbinafine
remain possible therapeutic options, in particular for less severe cases (localized and/or probable IA in
patients with mild/moderate immunosuppression and in the absence of previous mold-active azole
prophylaxis) or as second-line therapy in case of nephrotoxicity of amphotericin B or for maintenance
therapy. Posaconazole should be avoided because of its quasi-lack of in vitro activity and the occurrence
of breakthrough A. ustus IA with this drug. The role of echinocandins remains unclear, but this drug
class could be used as adjunctive therapy in severe cases.
Table 2. Current antifungal therapeutic options against Aspergillus calidoustus and other Aspergillus spp.
of section Usti.
Antifungal Drug Classes Evidences Comments
Amphotericin B
Relatively good in vitro activity
(MIC 0.25–2 µg/mL) [11,21]
Effective in a Galleria model [24]
Recommended as first-line on the basis of
optimal in vitro activity
(use lipid-based formulation)
Mold-active azoles
Relatively low in vitro activity
(MIC 2–16 µg/mL): isavuconazole >
voriconazole > posaconazole [11,21]
Voriconazole effective in a Galleria model of
infection [24]
Caveat: breakthrough infections frequently
reported (mainly under posaconazole, but
also voriconazole)
Pre-clinical and clinical data suggest possible
use in selected situations (e.g., less severe
cases or second-line/maintenance treatment,
absence of previous mold-active
azole prophylaxis)
Avoid posaconazole
Echinocandins Fungistatic effect: micafungin/anidulafungin
> caspofungin [21]
May be used in combination with either
amphotericin B or triazoles despite no
evidence of synergism
Few experience as monotherapy, use only if
no other alternatives (preferably micafungin
or anidulafungin)
Terbinafine
Relatively good in vitro activity
(MIC 0.25–1 µg/mL) [21,24]
Effective in a Galleria model of infection [24]
In vitro and in vivo (Galleria) synergism with
voriconazole, posaconazole and
isavuconazole [24]
In vitro antagonism with amphotericin B [24]
Accumulation in skin
(no sustained levels in blood) [30]
May be combined with voriconazole
(or isavuconazole) in selected situations
(see above, possible interest in patients with
skin lesions or alternative to amphotericin B
in case of intolerance)
Use as monotherapy not recommended
MIC: minimal inhibitory concentration, >: activity superior to.
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Novel broad-spectrum antifungal agents are needed to treat A. ustus and other refractory mold
infections. Some of them provided promising in vitro results. The Gwt1p inhibitor APX001A (E1210)
and olorofim (F901318), an inhibitor of pyrimidine biosynthesis, show good activity against Aspergillus
species of section Usti [33,34].
5. Conclusions
Aspergillus of section Usti (group ustus), in particular A. calidoustus, are increasingly recognized as
causal agents of IA, as a possible consequence of the extent of the population of transplant patients with
long-term immunosuppression and the widespread use of antifungal prophylaxis. This mold infection
is challenging because of its insidious course, atypical presentation and multidrug resistance. Clinicians
should suspect A. ustus IA in front of a transplant patient with persistently positive galactomannan
despite no clinical or radiological evidence of IA or in the presence of skin lesions or soft tissue
nodules. Optimal antifungal therapy still needs to be better defined. While amphotericin B is the most
active drug in vitro, other antifungals or drug combinations (e.g., voriconazole or isavuconazole +/−
terbinafine, adjuvant echinocandin) could be considered in selected situations.
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